Lots of interest from International and US users. GliaSite and it"s near term lauch was a hugh draw and Cesium's 5 year data/results was the talk of the show and a positive jolt as it showed the highest cure rates over any other competitive seeds and beats all the other treatment alternatives. We are all going to win with this stock. Revenue growth in 2012 will propell this stock big time. You'll never see these prices again.